1
|
Özil M, Balaydın HT, Dogan B, Şentürk M, Durdagi S. Efficient, rapid, and high-yield synthesis of aryl Schiff base derivatives and their in vitro and in silico inhibition studies of hCA I, hCA II, AChE, and BuChE. Arch Pharm (Weinheim) 2024; 357:e2300266. [PMID: 38593306 DOI: 10.1002/ardp.202300266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Revised: 03/12/2024] [Accepted: 03/13/2024] [Indexed: 04/11/2024]
Abstract
This study reports a rapid and efficient synthesis of four novel aryl Schiff base derivatives. Biological activity and molecular modeling studies were conducted to evaluate the inhibitory effects of these compounds on human carbonic anhydrases (hCA) and cholinesterases. The results indicate that the triazole-ring-containing compounds have strong inhibitory effects on hCA I, hCA II, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) targets. Besides comparing the Schiff bases synthesized in our study to reference molecules, we conducted in silico investigations to examine how these compounds interact with their targets. Our studies revealed that these compounds can occupy binding sites and establish interactions with crucial residues, thus inhibiting the functions of the targets. These findings have significant implications as they can be utilized to develop more potent compounds for treating the diseases that these target proteins play crucial roles in or to obtain drug precursors with enhanced efficacy.
Collapse
Affiliation(s)
- Musa Özil
- Department of Chemistry, The Faculty of Arts and Sciences, Recep Tayyip Erdogan University, Rize, Türkiye
| | - Halis T Balaydın
- Education Faculty, Recep Tayyip Erdogan University, Rize, Türkiye
| | - Berna Dogan
- Department of Chemistry, Istanbul Technical University, Istanbul, Türkiye
- Department of Biochemistry, School of Medicine, Bahçeşehir University, Istanbul, Türkiye
| | - Murat Şentürk
- Pharmacy Faculty, Agri Ibrahim Cecen University, Agri, Türkiye
| | - Serdar Durdagi
- Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, Istanbul, Türkiye
- Molecular Therapy Lab, Department of Pharmaceutical Chemistry, School of Pharmacy, Bahçeşehir University, Istanbul, Türkiye
| |
Collapse
|
2
|
Vignaux PA, Lane TR, Urbina F, Gerlach J, Puhl AC, Snyder SH, Ekins S. Validation of Acetylcholinesterase Inhibition Machine Learning Models for Multiple Species. Chem Res Toxicol 2023; 36:188-201. [PMID: 36737043 PMCID: PMC9945174 DOI: 10.1021/acs.chemrestox.2c00283] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Acetylcholinesterase (AChE) is an important enzyme and target for human therapeutics, environmental safety, and global food supply. Inhibitors of this enzyme are also used for pest elimination and can be misused for suicide or chemical warfare. Adverse effects of AChE pesticides on nontarget organisms, such as fish, amphibians, and humans, have also occurred as a result of biomagnifications of these toxic compounds. We have exhaustively curated the public data for AChE inhibition data and developed machine learning classification models for seven different species. Each set of models were built using up to nine different algorithms for each species and Morgan fingerprints (ECFP6) with an activity cutoff of 1 μM. The human (4075 compounds) and eel (5459 compounds) consensus models predicted AChE inhibition activity using external test sets from literature data with 81% and 82% accuracy, respectively, while the reciprocal cross (76% and 82% percent accuracy) was not species-specific. In addition, we also created machine learning regression models for human and eel AChE inhibition to return a predicted IC50 value for a queried molecule. We did observe an improved species specificity in the regression models, where a human support vector regression model of human AChE inhibition (3652 compounds) predicted the IC50s of the human test set to a better extent than the eel regression model (4930 compounds) on the same test set, based on mean absolute percentage error (MAPE = 9.73% vs 13.4%). The predictive power of these models certainly benefits from increasing the chemical diversity of the training set, as evidenced by expanding our human classification model by incorporating data from the Tox21 library of compounds. Of the 10 compounds we tested that were predicted active by this expanded model, two showed >80% inhibition at 100 μM. This machine learning approach therefore offers the ability to rapidly score massive libraries of molecules against the models for AChE inhibition that can then be selected for future in vitro testing to identify potential toxins. It also enabled us to create a public website, MegaAChE, for single-molecule predictions of AChE inhibition using these models at megaache.collaborationspharma.com.
Collapse
Affiliation(s)
- Patricia A Vignaux
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Thomas R Lane
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Fabio Urbina
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Jacob Gerlach
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Ana C Puhl
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Scott H Snyder
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Sean Ekins
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| |
Collapse
|
3
|
Sun S, Shi T, Peng Y, Zhang H, Zhuo L, Peng X, Li Q, Wang M, Wang S, Wang Z. Discovery of pyrrole derivatives as acetylcholinesterase-sparing butyrylcholinesterase inhibitor. Front Pharmacol 2022; 13:1043397. [PMID: 36561337 PMCID: PMC9763612 DOI: 10.3389/fphar.2022.1043397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 11/23/2022] [Indexed: 12/12/2022] Open
Abstract
Inspired by the crucial roles of (hetero)aryl rings in cholinesterase inhibitors and the pyrrole ring in new drug discovery, we synthesized 19 pyrrole derivatives and investigated their cholinesterase inhibitory activity. As a result, compounds 3o, 3p, and 3s with a 1,3-diaryl-pyrrole skeleton showed high selectivity toward BChE over AChE with a best IC50 value of 1.71 ± 0.087 µM, which were comparable to donepezil. The pharmaceutical potential of these structures was further predicted and compounds 3o and 3p were proved to meet well with the Lipinsky's five rules. In combination of the inhibition kinetic studies with the results of molecular docking, we concluded that compound 3p inhibited BChE in a mixed competitive mode. This research has proved the potential of the 1,3-diaryl-pyrrole skeleton as a kind of selective BChE inhibitor.
Collapse
Affiliation(s)
- Shouyuan Sun
- Lanzhou University Second Hospital, Lanzhou, China
| | - Tao Shi
- School of Pharmacy, Lanzhou University, Lanzhou, China
| | - Yan Peng
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, China
| | - Honghua Zhang
- School of Pharmacy, Lanzhou University, Lanzhou, China
| | - Linsheng Zhuo
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, China
| | - Xue Peng
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, China
| | - Qien Li
- Tibetan Medical College, Qinghai University, Xining, China
| | - Manxia Wang
- Lanzhou University Second Hospital, Lanzhou, China,*Correspondence: Manxia Wang, ; Shuzhi Wang, ; Zhen Wang,
| | - Shuzhi Wang
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, China,*Correspondence: Manxia Wang, ; Shuzhi Wang, ; Zhen Wang,
| | - Zhen Wang
- School of Pharmacy, Lanzhou University, Lanzhou, China,School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, China,*Correspondence: Manxia Wang, ; Shuzhi Wang, ; Zhen Wang,
| |
Collapse
|
4
|
Arslan T, Senturk M, Karagoz L, Karagoz Y, Ekinci D, Efe A, Türkoğlu EA, Uras F. Synthesis
, in vitro
and
in silico
Biological Studies of Sulfonamide Chalcones as Esterase Inhibitors. ChemistrySelect 2022. [DOI: 10.1002/slct.202202993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Tayfun Arslan
- Department of Chemistry Faculty of Science and Art Giresun University 28200 Giresun Türkiye
| | - Murat Senturk
- Department of Biochemistry Faculty of Pharmacy Agri Ibrahim Cecen University 04100 Agri Türkiye
| | - Lütfi Karagoz
- Department of Biochemistry Faculty of Pharmacy Marmara University 34668 Istanbul Türkiye
| | - Yalcin Karagoz
- Department of Biochemistry Faculty of Pharmacy Agri Ibrahim Cecen University 04100 Agri Türkiye
| | - Deniz Ekinci
- Department of Agricultural Biotechnology Faculty of Agriculture Ondokuz Mayıs University 55139 Samsun Türkiye
| | - Asiye Efe
- Institute of Graduate Education Agri Ibrahim Cecen University 04100 Agri Türkiye
| | - Emir Alper Türkoğlu
- Department of Pharmaceutical Biotechnology Faculty of Pharmacy University of Health Sciences Turkey 34668 Istanbul Türkiye
| | - Fikriye Uras
- Department of Biochemistry Faculty of Pharmacy Marmara University 34668 Istanbul Türkiye
| |
Collapse
|
5
|
Arshad JZ, Hanif M. Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors. RSC Med Chem 2022; 13:1127-1149. [PMID: 36325396 PMCID: PMC9579940 DOI: 10.1039/d2md00175f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 07/28/2022] [Indexed: 07/31/2023] Open
Abstract
The versatile structural motif of hydroxypyrone is found in natural products and can be easily converted into hydroxypyridone and hydroxythiopyridone analogues. The favourable toxicity profile and ease of functionalization to access a vast library of compounds make them an ideal structural scaffold for drug design and discovery. This versatile scaffold possesses excellent metal chelating properties that can be exploited for chelation therapy in clinics. Deferiprone [1,2-dimethyl-3-hydroxy-4(1H)-one] was the first orally active chelator to treat iron overload in thalassemia major. Metal complexes of hydroxy-(thio)pyr(id)ones have been investigated as magnetic resonance imaging contrast agents, and anticancer and antidiabetic agents. In recent years, this compound class has demonstrated potential in discovering and developing metalloenzyme inhibitors. This review article summarizes recent literature on hydroxy-(thio)pyr(id)ones as inhibitors for metalloenzymes such as histone deacetylases, tyrosinase and metallo-β-lactamase. Different approaches to the design of hydroxy-(thio)pyr(id)ones and their biological properties against selected metalloenzymes are discussed.
Collapse
Affiliation(s)
- Jahan Zaib Arshad
- Department of Chemistry, Government College Women University Sialkot Sialkot Pakistan
| | - Muhammad Hanif
- School of Chemical Sciences, University of Auckland Private Bag 92019 Auckland 1142 New Zealand (+64) 9 373 7599 ext. 87422
- MacDiarmid Institute for Advanced Materials and Nanotechnology Wellington New Zealand
| |
Collapse
|
6
|
Zhang H, Wang Y, Wang Y, Li X, Wang S, Wang Z. Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease. Eur J Med Chem 2022; 240:114606. [PMID: 35858523 DOI: 10.1016/j.ejmech.2022.114606] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 07/08/2022] [Accepted: 07/09/2022] [Indexed: 12/17/2022]
Abstract
Alzheimer's disease (AD), as the fourth leading cause of death among the elderly worldwide, has brought enormous challenge to the society. Due to its extremely complex pathogeneses, the development of multi-target directed ligands (MTDLs) becomes the major strategy for combating AD. Carbamate moiety, as an essential building block in the development of MTDLs, exhibits structural similarity to neurotransmitter acetylcholine (ACh) and has piqued extensive attention in discovering multifunctional cholinesterase inhibitors. To date, numerous preclinical studies demonstrate that carbamate-based cholinesterase inhibitors can prominently increase the level of ACh and improve cognition impairments and behavioral deficits, providing a privileged strategy for the treatment of AD. Based on the recent research focus on the novel cholinesterase inhibitors with multiple biofunctions, this review aims at summarizing and discussing the most recent studies excavating the potential carbamate-based MTDLs with cholinesterase inhibition efficacy, to accelerate the pace of pleiotropic cholinesterase inhibitors for coping AD.
Collapse
Affiliation(s)
- Honghua Zhang
- School of Pharmacy, Lanzhou University, Lanzhou, 730000, China
| | - Yuying Wang
- State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, China
| | - Yuqing Wang
- School of Pharmacy, Lanzhou University, Lanzhou, 730000, China
| | - Xuelin Li
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
| | - Shuzhi Wang
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
| | - Zhen Wang
- The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
| |
Collapse
|
7
|
Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine. Int J Mol Sci 2022; 23:ijms23031247. [PMID: 35163169 PMCID: PMC8835618 DOI: 10.3390/ijms23031247] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 01/13/2022] [Accepted: 01/20/2022] [Indexed: 12/24/2022] Open
Abstract
The antioxidant/pro-oxidant activity of drugs and dietary molecules and their role in the maintenance of redox homeostasis, as well as the implications in health and different diseases, have not yet been fully evaluated. In particular, the redox activity and other interactions of drugs with essential redox metal ions, such as iron and copper, need further investigation. These metal ions are ubiquitous in human nutrition but also widely found in dietary supplements and appear to exert major effects on redox homeostasis in health, but also on many diseases of free radical pathology. In this context, the redox mechanistic insights of mainly three prototype groups of drugs, namely alpha-ketohydroxypyridines (alpha-hydroxypyridones), e.g., deferiprone, anthraquinones, e.g., doxorubicin and thiosemicarbazones, e.g., triapine and their metal complexes were examined; details of the mechanisms of their redox activity were reviewed, with emphasis on the biological implications and potential clinical applications, including anticancer activity. Furthermore, the redox properties of these three classes of chelators were compared to those of the iron chelating drugs and also to vitamin C, with an emphasis on their potential clinical interactions and future clinical application prospects in cancer, neurodegenerative and other diseases.
Collapse
|
8
|
Çınar E, Başaran E, Erdoğan Ö, Çakmak R, Boğa M, Çevik Ö. Heterocyclic Schiff base derivatives containing pyrazolone moiety: Synthesis, characterization, and in vitro biological studies. J CHIN CHEM SOC-TAIP 2021. [DOI: 10.1002/jccs.202100357] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Ercan Çınar
- Department of Nursing, Faculty of Health Sciences Batman University Batman Turkey
| | - Eyüp Başaran
- Department of Chemistry and Chemical Processing Technologies, Vocational School of Technical Sciences Batman University Batman Turkey
| | - Ömer Erdoğan
- Department of Biochemistry, Faculty of Medicine Adnan Menderes University Aydın Turkey
| | - Reşit Çakmak
- Medical Laboratory Techniques Program, Vocational School of Health Services Batman University Batman Turkey
| | - Mehmet Boğa
- Department of Analytical Chemistry, Faculty of Pharmacy Dicle University Diyarbakır Turkey
| | - Özge Çevik
- Department of Biochemistry, Faculty of Medicine Adnan Menderes University Aydın Turkey
| |
Collapse
|
9
|
New silver Nheterocyclic carbenes complexes: Synthesis, molecular docking study and biological activities evaluation as cholinesterase inhibitors and antimicrobials. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2021.130399] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
10
|
Bagri K, Kumar A, Manisha, Kumar P. Computational Studies on Acetylcholinesterase Inhibitors: From Biochemistry to Chemistry. Mini Rev Med Chem 2021; 20:1403-1435. [PMID: 31884928 DOI: 10.2174/1389557520666191224144346] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 10/23/2019] [Accepted: 10/28/2019] [Indexed: 11/22/2022]
Abstract
Acetylcholinesterase inhibitors are the most promising therapeutics for Alzheimer's disease treatment as these prevent the loss of acetylcholine and slows the progression of the disease. The drugs approved for the management of Alzheimer's disease by the FDA are acetylcholinesterase inhibitors but are associated with side effects. Consistent and stringent efforts by the researchers with the help of computational methods opened new ways of developing novel molecules with good acetylcholinesterase inhibitory activity. In this manuscript, we reviewed the studies that identified the essential structural features of acetylcholinesterase inhibitors at the molecular level as well as the techniques like molecular docking, molecular dynamics, quantitative structure-activity relationship, virtual screening, and pharmacophore modelling that were used in designing these inhibitors.
Collapse
Affiliation(s)
- Kiran Bagri
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science & Technology, Hisar 125001, India
| | - Ashwani Kumar
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science & Technology, Hisar 125001, India
| | - Manisha
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science & Technology, Hisar 125001, India
| | - Parvin Kumar
- Department of Chemistry, Kurukshetra University, Kurukshetra, India
| |
Collapse
|
11
|
Abstract
Alzheimer's disease (AD) is a significant health crisis, and current treatments provide only limited benefits to cognition at the cost of serious side effects. Recently, virtual screening techniques such as ligand-based virtual screening (LBVS) and structure-based virtual screening (SBVS) have emerged as powerful drug discovery tools for identifying potential ligands of a biological target from a large database of chemical structures. The cholinesterases are an AD target particularly well suited for drug discovery using virtual screening due to their well-characterized active sites and comprehensive understanding of the structure-activity relationships of existing inhibitors. Over the last 5 years (2015-2020), at least 15 studies have used virtual screening techniques to discover potent new cholinesterase inhibitors. Herein we review how LBVS and SBVS have been applied individually or in tandem to discover novel acetylcholinesterase and butyrylcholinesterase inhibitors for AD, and highlight the need to confirm in vitro activity of screening compounds.
Collapse
Affiliation(s)
- Jared A. Miles
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Benjamin P. Ross
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| |
Collapse
|
12
|
Vignaux PA, Minerali E, Lane TR, Foil DH, Madrid PB, Puhl AC, Ekins S. The Antiviral Drug Tilorone Is a Potent and Selective Inhibitor of Acetylcholinesterase. Chem Res Toxicol 2021; 34:1296-1307. [PMID: 33400519 DOI: 10.1021/acs.chemrestox.0c00466] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Acetylcholinesterase (AChE) is an important drug target in neurological disorders like Alzheimer's disease, Lewy body dementia, and Parkinson's disease dementia as well as for other conditions like myasthenia gravis and anticholinergic poisoning. In this study, we have used a combination of high-throughput screening, machine learning, and docking to identify new inhibitors of this enzyme. Bayesian machine learning models were generated with literature data from ChEMBL for eel and human AChE inhibitors as well as butyrylcholinesterase inhibitors (BuChE) and compared with other machine learning methods. High-throughput screens for the eel AChE inhibitor model identified several molecules including tilorone, an antiviral drug that is well-established outside of the United States, as a newly identified nanomolar AChE inhibitor. We have described how tilorone inhibits both eel and human AChE with IC50's of 14.4 nM and 64.4 nM, respectively, but does not inhibit the closely related BuChE IC50 > 50 μM. We have docked tilorone into the human AChE crystal structure and shown that this selectivity is likely due to the reliance on a specific interaction with a hydrophobic residue in the peripheral anionic site of AChE that is absent in BuChE. We also conducted a pharmacological safety profile (SafetyScreen44) and kinase selectivity screen (SelectScreen) that showed tilorone (1 μM) only inhibited AChE out of 44 toxicology target proteins evaluated and did not appreciably inhibit any of the 485 kinases tested. This study suggests there may be a potential role for repurposing tilorone or its derivatives in conditions that benefit from AChE inhibition.
Collapse
Affiliation(s)
- Patricia A Vignaux
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Eni Minerali
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Thomas R Lane
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Daniel H Foil
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Peter B Madrid
- SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025, United States
| | - Ana C Puhl
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| | - Sean Ekins
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States
| |
Collapse
|
13
|
Hv S, Raj A, K G, S C, K S. Kinetics and computational analysis of cholinesterase inhibition by REVERC3, a bisdemethoxycurcumin-rich Curcuma longa extract: Relevance to the treatment of Alzheimer's disease. SAGE Open Med 2020; 8:2050312120973499. [PMID: 33282298 PMCID: PMC7686599 DOI: 10.1177/2050312120973499] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 10/26/2020] [Indexed: 12/06/2022] Open
Abstract
Objectives: Cholinesterase inhibition is a common strategy to treat
Alzheimer’s disease. In this study, we have investigated the cholinesterase
inhibitory effects of a first-of-its-kind turmeric extract (REVERC3) having
enriched content of bisdemethoxycurcumin as major active curcuminoid.
Methods: The inhibition studies were performed using Ellman’s
colorimetric assay. The kinetics of acetylcholinesterase and
butyrylcholinesterase was determined in the presence of REVERC3 using the
Lineweaver–Burk double reciprocal plots. Furthermore, we used AutoDock tools to
predict the binding of bisdemethoxycurcumin with the active sites of
cholinesterases. Results: REVERC3 showed 4.8- and 5.39-fold higher
inhibitory potential of acetylcholinesterase and butyrylcholinesterase with IC50
values of 29.08 and 33.59 µg/mL, respectively, compared to the regular turmeric
extract. The mode of binding of REVERC3 was competitive in the case of
acetylcholinesterase while it was uncompetitive for the inhibition of
butyrylcholinesterase. Docking analysis revealed that bisdemethoxycurcumin, the
major constituent of REVERC3, has different preferences of binding in the active
sites of acetylcholinesterase and butyrylcholinesterase. However, the best
binding pose predictions are in line with the experimental binding mode of the
cholinesterases. Conclusion: These results indicate that
bisdemethoxycurcumin-enriched turmeric extract could improve the cholinergic
functions via dual inhibition of cholinesterases. However, the predominant role
of bisdemethoxycurcumin in REVERC3 must be further validated using preclinical
studies and clinical trials.
Collapse
Affiliation(s)
- Sudeep Hv
- R&D Center for Excellence, Vidya Herbs Pvt. Ltd., Bangalore, India
| | - Amritha Raj
- R&D Center for Excellence, Vidya Herbs Pvt. Ltd., Bangalore, India
| | - Gouthamchandra K
- R&D Center for Excellence, Vidya Herbs Pvt. Ltd., Bangalore, India
| | - Chandrappa S
- R&D Center for Excellence, Vidya Herbs Pvt. Ltd., Bangalore, India
| | - Shyamprasad K
- R&D Center for Excellence, Vidya Herbs Pvt. Ltd., Bangalore, India
| |
Collapse
|
14
|
|
15
|
Jiang X, Zhou T, Bai R, Xie Y. Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities. J Med Chem 2020; 63:14470-14501. [PMID: 33023291 DOI: 10.1021/acs.jmedchem.0c01480] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Iron plays an essential role in all living cells because of its unique chemical properties. It is also the most abundant trace element in mammals. However, when iron is present in excess or inappropriately located, it becomes toxic. Excess iron can become involved in free radical formation, resulting in oxidative stress and cellular damage. Iron chelators are used to treat serious pathological disorders associated with systemic iron overload. Hydroxypyridinones stand out for their outstanding chelation properties, including high selectivity for Fe3+ in the biological environment, ease of derivatization, and good biocompatibility. Herein, we overview the potential for multifunctional hydroxypyridinone-based chelators to be used as therapeutic agents against a wide range of diseases associated either with systemic or local elevated iron levels.
Collapse
Affiliation(s)
- Xiaoying Jiang
- Collaborative Innovation Centre of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, 310014, P.R. China
| | - Tao Zhou
- School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, 310018, P.R. China
| | - Renren Bai
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, P.R. China
| | - Yuanyuan Xie
- Collaborative Innovation Centre of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, 310014, P.R. China.,College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, P.R. China
| |
Collapse
|
16
|
Akin Kazancioglu E, Senturk M. Synthesis of N-phenylsulfonamide derivatives and investigation of some esterase enzymes inhibiting properties. Bioorg Chem 2020; 104:104279. [PMID: 32980674 DOI: 10.1016/j.bioorg.2020.104279] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 08/11/2020] [Accepted: 09/11/2020] [Indexed: 11/30/2022]
Abstract
In this study, synthesis of nine N-phenylsulfonamide derivatives was designed by starting from aniline, which is the simplest aromatic amine. These compounds were obtained in yields between 69 and 95%. Inhibitory properties of synthesized compounds on carbonic anhydrase I (CA I), CA II isoenzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes were investigated. Inhibitors of CA isoenzymes are important therapeutic targets, particularly due to their preventive/activation potential in the treatment of diseases such as edema, glaucoma, cancer and osteoporosis. Cholinesterase inhibitors are valuable compounds that can be used in many different therapeutic applications, including Alzheimer's disease. The compound 8 for CA I, AChE and BChE, 2 for CA II showed a very active inhibition profile (KI 45.7 ± 0.46 for CA I, 33.5 ± 0.38 nM for CA II, 31.5 ± 0.33 nM for AChE and 24.4 ± 0.29 nM for BChE). The results indicate that these N-phenyl-sulfonamide derivatives are potent CA and cholinesterases and new potential drugs.
Collapse
Affiliation(s)
- Elif Akin Kazancioglu
- Vocational High School of Health Services, Kilis 7 Aralik University, 79000 Kilis, Turkey; Advanced Technology Application and Research Center, Kilis 7 Aralik University, 79000 Kilis, Turkey.
| | - Murat Senturk
- Pharmacy Faculty, Agri Ibrahim Cecen University, 04100 Agri, Turkey
| |
Collapse
|
17
|
Bortolami M, Pandolfi F, De Vita D, Carafa C, Messore A, Di Santo R, Feroci M, Costi R, Chiarotto I, Bagetta D, Alcaro S, Colone M, Stringaro A, Scipione L. New deferiprone derivatives as multi-functional cholinesterase inhibitors: design, synthesis and in vitro evaluation. Eur J Med Chem 2020; 198:112350. [PMID: 32380385 DOI: 10.1016/j.ejmech.2020.112350] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 04/15/2020] [Accepted: 04/16/2020] [Indexed: 01/19/2023]
Abstract
In order to obtain multi-functional molecules for Alzheimer's disease, a series of deferiprone derivatives has been synthesized and evaluated in vitro with the hypothesis that they can restore the cholinergic tone and attenuate the dyshomeostasis of the metals mainly involved in the pathology. These compounds were designed as dual binding site AChE inhibitors: they possess an arylalkylamine moiety connected via an alkyl chain to a 3-hydroxy-4-pyridone fragment, to allow the simultaneous interaction with catalytic active site (CAS) and peripheral anionic site (PAS) of the enzyme. Deferiprone moiety and 2-aminopyridine, 2-aminopyrimidine or 2,4-diaminopyrimidine groups have been incorporated into these compounds, in order to obtain molecules potentially able to chelate bio-metals colocalized in Aβ plaques and involved in the generation of radical species. Synthesized compounds were tested by enzymatic inhibition studies towards EeAChE and eqBChE using Ellman's method. The most potent EeAChE inhibitor is compound 5a, with a Ki of 788 ± 51 nM, while the most potent eqBChE inhibitors are compounds 12 and 19, with Ki values of 182 ± 18 nM and 258 ± 25 nM respectively. Selected compounds, among the most potent cholinesterases inhibitors, were able to form complex with iron and in some cases with copper and zinc. Moreover, these compounds were characterized by low toxicity on U-87 MG Cell Line from human brain (glioblastoma astrocytoma).
Collapse
Affiliation(s)
- Martina Bortolami
- Department of Chimica e Tecnologia del Farmaco, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy
| | - Fabiana Pandolfi
- Department of Scienze di Base e Applicate per l'Ingegneria, Sapienza University of Rome, via Castro Laurenziano 7, I-00161, Rome, Italy
| | - Daniela De Vita
- Department of Environmental Biology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy
| | - Camilla Carafa
- Department of Chimica e Tecnologia del Farmaco, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy
| | - Antonella Messore
- Department of Chimica e Tecnologia del Farmaco, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy
| | - Roberto Di Santo
- Department of Chimica e Tecnologia del Farmaco, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy; Istituto Pasteur, Fondazione Cenci Bolognetti, Department of Chemistry and Technology of Drug, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy
| | - Marta Feroci
- Department of Scienze di Base e Applicate per l'Ingegneria, Sapienza University of Rome, via Castro Laurenziano 7, I-00161, Rome, Italy
| | - Roberta Costi
- Department of Chimica e Tecnologia del Farmaco, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy; Istituto Pasteur, Fondazione Cenci Bolognetti, Department of Chemistry and Technology of Drug, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy
| | - Isabella Chiarotto
- Department of Scienze di Base e Applicate per l'Ingegneria, Sapienza University of Rome, via Castro Laurenziano 7, I-00161, Rome, Italy
| | - Donatella Bagetta
- Net4Science s.r.l., Campus universitario "S. Venuta", Viale Europa, 88100, Catanzaro, Italy
| | - Stefano Alcaro
- Net4Science s.r.l., Campus universitario "S. Venuta", Viale Europa, 88100, Catanzaro, Italy; Dipartimento di Scienze della Salute, Università"Magna Græcia" di Catanzaro, Viale Europa, 88100, Catanzaro, Italy.
| | - Marisa Colone
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena, 00161, Rome, Italy
| | - Annarita Stringaro
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena, 00161, Rome, Italy
| | - Luigi Scipione
- Department of Chimica e Tecnologia del Farmaco, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy.
| |
Collapse
|
18
|
Cavdar H, Senturk M, Guney M, Durdagi S, Kayik G, Supuran CT, Ekinci D. Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies. J Enzyme Inhib Med Chem 2019; 34:429-437. [PMID: 30734597 PMCID: PMC6327988 DOI: 10.1080/14756366.2018.1543288] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 10/26/2018] [Accepted: 10/30/2018] [Indexed: 11/18/2022] Open
Abstract
Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) inhibitors are interesting compounds for different therapeutic applications, among which Alzheimer's disease. Here, we investigated the inhibition of these cholinesterases with uracil derivatives. The mechanism of inhibition of these enzymes was observed to be due to obstruction of the active site entrance by the inhibitors scaffold. Molecular docking and molecular dynamics (MD) simulations demonstrated the possible key interactions between the studied ligands and amino acid residues at different regions of the active sites of AChE and BuChE. Being diverse of the classical AChE and BuChE inhibitors, the investigated uracil derivatives may be used as lead molecules for designing new therapeutically effective enzyme inhibitors.
Collapse
Affiliation(s)
- Huseyin Cavdar
- Department of Mathematics and Science Education, Education Faculty, Dumlupınar University, Kutahya, Turkey
| | - Murat Senturk
- Department of Basic Sciences of Pharmacy, Pharmacy Faculty, Agri Ibrahim Cecen University, Agri, Turkey
| | - Murat Guney
- Department of Chemistry, Science and Art Faculty, Agri Ibrahim Cecen University, Agri, Turkey
| | - Serdar Durdagi
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, Bahcesehir University, School of Medicine, Istanbul, Turkey
| | - Gulru Kayik
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, Bahcesehir University, School of Medicine, Istanbul, Turkey
| | - Claudiu T. Supuran
- Department of Neurofarba, University of Florence, Sesto Fiorentino (Firenze), Italy
| | - Deniz Ekinci
- Department of Agricultural Biotechnology, Agriculture Faculty, Ondokuz Mayis University, Samsun, Turkey
| |
Collapse
|
19
|
Özil M, Balaydın HT, Şentürk M. Synthesis of 5-methyl-2,4-dihydro-3H-1,2,4-triazole-3-one’s aryl Schiff base derivatives and investigation of carbonic anhydrase and cholinesterase (AChE, BuChE) inhibitory properties. Bioorg Chem 2019; 86:705-713. [DOI: 10.1016/j.bioorg.2019.02.045] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2018] [Revised: 02/12/2019] [Accepted: 02/21/2019] [Indexed: 12/21/2022]
|
20
|
Cappai R, Chand K, Lachowicz JI, Chaves S, Gano L, Crisponi G, Nurchi VM, Peana M, Zoroddu MA, Santos MA. A new tripodal-3-hydroxy-4-pyridinone for iron and aluminium sequestration: synthesis, complexation and in vivo studies. NEW J CHEM 2018. [DOI: 10.1039/c8nj00116b] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A new highly efficient tris-hydroxypyridinone chelator for iron and aluminum, with promising capacity as a potential metal decorporation agent.
Collapse
Affiliation(s)
- Rosita Cappai
- Centro de Química Estrutural
- Instituto Superior Técnico
- Universidade de Lisboa
- 1049-001 Lisboa
- Portugal
| | - Karam Chand
- Centro de Química Estrutural
- Instituto Superior Técnico
- Universidade de Lisboa
- 1049-001 Lisboa
- Portugal
| | - Joanna I. Lachowicz
- Dipartimento di Scienze Chimiche e Geologiche
- Università di Cagliari
- Cittadella Universitaria
- 09042 Monserrato-Cagliari
- Italy
| | - Sílvia Chaves
- Centro de Química Estrutural
- Instituto Superior Técnico
- Universidade de Lisboa
- 1049-001 Lisboa
- Portugal
| | - Lurdes Gano
- Centro de Ciências e Tecnologias Nucleares (C2TN)
- Instituto Superior Técnico
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| | - Guido Crisponi
- Dipartimento di Scienze Chimiche e Geologiche
- Università di Cagliari
- Cittadella Universitaria
- 09042 Monserrato-Cagliari
- Italy
| | - Valeria M. Nurchi
- Dipartimento di Scienze Chimiche e Geologiche
- Università di Cagliari
- Cittadella Universitaria
- 09042 Monserrato-Cagliari
- Italy
| | - Massimiliano Peana
- Dipartimento di Chimica e Farmacia
- Università di Sassari
- 07100 Sassari
- Italy
| | | | - M. Amélia Santos
- Centro de Química Estrutural
- Instituto Superior Técnico
- Universidade de Lisboa
- 1049-001 Lisboa
- Portugal
| |
Collapse
|
21
|
Hiremathad A, Chand K, Tolayan L, Rajeshwari, Keri RS, Esteves AR, Cardoso SM, Chaves S, Santos MA. Hydroxypyridinone-benzofuran hybrids with potential protective roles for Alzheimer´s disease therapy. J Inorg Biochem 2017; 179:82-96. [PMID: 29182921 DOI: 10.1016/j.jinorgbio.2017.11.015] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 11/07/2017] [Accepted: 11/17/2017] [Indexed: 12/14/2022]
Abstract
A series of (3-hydroxy-4-pyridinone)-benzofuran hybrids have been developed and studied as potential multitargeting drugs for Alzheimer's disease (AD). Their design envisaged mainly to mimic the donepezil drug, a marketed inhibitor of acetylcholinesterase (AChE), and to endow the conjugate molecules with extra-properties such as metal chelation, radical scavenging and inhibition of amyloid peptide (Aβ) aggregation. Thus, a set of eleven new hybrid compounds was developed and evaluated for chemical and biological properties, in solution and in neuronal cell environment. The results are discussed in terms of the type of substituents on both main moieties and the linker size. The closest similarity with donepezil, in terms of AChE inhibitory activity, was obtained for the O-benzyl-hydroxypyridinone hybrids containing a 2-methylene linker, although still less active than the drug. However, the free-hydroxypyridinone hybrids present higher activity for the Aβ aggregation inhibition, metal chelating capacity and radical scavenging activity. Overall, some compounds demonstrated capacity to exert a multiple action by hitting three- (7d) or four- (8d, 8f) pathophysiological targets of AD. Furthermore, the compounds showed neuroprotective effects in neuronal cells subjected to model stressors of AD, but not significant dependence on the substituent groups. Importantly, the compounds evidenced drug-likeness properties, including good membrane permeability.
Collapse
Affiliation(s)
- Asha Hiremathad
- Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal; Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Kanakapura, Ramanagara, Bangalore 562112, India
| | - Karam Chand
- Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal
| | - Lori Tolayan
- Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal
| | - Rajeshwari
- Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal
| | - Rangappa S Keri
- Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Kanakapura, Ramanagara, Bangalore 562112, India.
| | - A Raquel Esteves
- CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; Institute of Cell and Molecular Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Sandra M Cardoso
- CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; Institute of Cell and Molecular Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Sílvia Chaves
- Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal
| | - M Amélia Santos
- Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal.
| |
Collapse
|